Earnings Recaps

Browse reported earnings of the most popular stocks

Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026 Mar 2, 2026 Feb 28, 2026 Feb 27, 2026 Feb 26, 2026 Feb 25, 2026 Feb 24, 2026 Feb 23, 2026 Feb 21, 2026 Feb 20, 2026 Feb 19, 2026 Feb 18, 2026 Feb 17, 2026 Feb 14, 2026 Feb 13, 2026 Feb 12, 2026 Feb 11, 2026 Feb 10, 2026 Feb 9, 2026 Feb 7, 2026 Feb 6, 2026 Feb 5, 2026 Feb 4, 2026 Feb 3, 2026 Feb 2, 2026 Jan 31, 2026 Jan 30, 2026 Jan 29, 2026 Jan 28, 2026 Jan 27, 2026 Jan 26, 2026 Jan 23, 2026 Jan 22, 2026 Jan 21, 2026 Jan 20, 2026 Jan 17, 2026 Jan 16, 2026 Jan 15, 2026 Jan 14, 2026 Jan 9, 2026 Jan 8, 2026 Jan 7, 2026 Jan 6, 2026 Dec 19, 2025 Dec 18, 2025 Dec 17, 2025 Dec 12, 2025 Dec 11, 2025 Dec 10, 2025 Dec 9, 2025 Dec 6, 2025 Dec 5, 2025 Dec 4, 2025 Dec 3, 2025 Dec 2, 2025 Dec 1, 2025 Nov 27, 2025 Nov 26, 2025 Nov 25, 2025 Nov 24, 2025 Nov 23, 2025 Nov 21, 2025 Nov 20, 2025 Nov 19, 2025 Nov 18, 2025 Nov 17, 2025 Nov 15, 2025 Nov 14, 2025 Nov 13, 2025 Nov 12, 2025 Nov 11, 2025 Nov 10, 2025 Nov 9, 2025 Nov 8, 2025 Nov 7, 2025 Nov 6, 2025 Nov 5, 2025 Nov 4, 2025 Nov 1, 2025 Oct 31, 2025 Oct 30, 2025 Oct 29, 2025 Oct 28, 2025 Oct 27, 2025 Oct 25, 2025 Oct 24, 2025 Oct 23, 2025 Oct 22, 2025 Oct 21, 2025 Oct 17, 2025 Oct 16, 2025 Oct 15, 2025 Oct 14, 2025 Oct 9, 2025 Oct 8, 2025 Oct 7, 2025 Sep 25, 2025 Sep 23, 2025 Sep 17, 2025 Sep 16, 2025 Sep 11, 2025 Sep 10, 2025 Sep 9, 2025 Sep 5, 2025 Sep 4, 2025 Sep 3, 2025 Sep 2, 2025 Sep 1, 2025 Aug 28, 2025 Aug 26, 2025 Aug 25, 2025 Aug 22, 2025 Aug 21, 2025 Aug 20, 2025 Aug 19, 2025 Aug 18, 2025 Aug 15, 2025 Aug 14, 2025 Aug 13, 2025 Aug 12, 2025 Aug 11, 2025 Aug 9, 2025 Aug 8, 2025 Aug 2, 2025 Aug 1, 2025 Jul 30, 2025 Jul 29, 2025 Jul 25, 2025
6 companies Today

Adobe Inc.

ADBE Q1 2026
Reported: 2026-03-13

Adobe reported a robust Q1 for FY 2026, achieving $6.4 billion in revenue with a notable 11% year-over-year growth, while transitioning to an AI-centric business model under new leadership.

Key takeaways
  • Surpassed 850 million monthly active users across Acrobat, Creative Cloud, Express, and Firefly, reflecting a 17% year-over-year increase.
  • Non-GAAP earnings per share rose 19% year-over-year to $6.06, indicating solid profitability amidst expanding AI initiatives.
  • Achieved over 30% year-over-year growth in Adobe Experience Platform (AEP) and related applications, showcasing strong demand for AI-driven enterprise solutions.
  • Transitioning leadership as CEO Shantanu Narayen announces plans to retire, focusing on ensuring a smooth succession.
  • Continued investment in AI-first products, including Adobe Firefly and Adobe GenStudio, signaling a commitment to capitalize on emerging market opportunities.

Mission Produce, Inc.

AVO Q1 2026
Reported: 2026-03-13

Mission Produce, Inc. started fiscal 2026 strong, achieving a 14% increase in avocado volumes and expanding gross margins despite challenging pricing dynamics. The company is well-positioned for growth, bolstered by the upcoming Calavo acquisition.

Key takeaways
  • Q1 avocado volumes increased by 14%, indicating effective volume management despite fluctuating prices.
  • Expanded gross margins and improved adjusted EBITDA highlight the company's operational strengths.
  • The inclusion of avocados in the USDA's updated Dietary Guidelines supports continued consumption growth.
  • The Calavo acquisition is seen as a strategic move to enhance Mission's core business and expand into prepared foods.
  • Domestic GLP-1 penetration is driving increased avocado consumption, reinforcing the growth potential within the broader health and wellness trend.

Champions Oncology, Inc.

CSBR Q3 2026
Reported: 2026-03-13

Champions Oncology reported a strong third quarter, achieving record services revenue and maintaining positive adjusted EBITDA for the third consecutive quarter, despite a slight year-over-year decline in total revenue.

Key takeaways
  • Core study revenue reached a record $16.6 million, growing approximately 32% year-over-year.
  • The company remains on track for full-year revenue growth and positive adjusted EBITDA while investing in data and drug discovery initiatives.
  • Early momentum is evident in the data business with new deals closed and revenue expected in the fourth quarter.
  • Champions is committed to maintaining disciplined capital allocation while investing for future growth without diluting shares.

Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector
Loading...